论文部分内容阅读
将确诊的未用过胰岛素的2型糖尿病患者48人,随机分为2组,其中强化治疗组24人,常规治疗组24人。另选择健康体检者24人做为对照。观察胰岛素强化治疗与常规治疗前后血清单核细胞趋化蛋白-1(MCP-1)的变化。结果:(1)胰岛素强化治疗组与常规治疗组MCP-1的水平在治疗前差异无显著性。两组治疗前与正常对照组比较,差异显著。(2)两组治疗前后MCP-1水平比较,差异显著P<0.05,强化组下降更明显P<0.01。(3)胰岛素强化治疗组与常规治疗组治疗前后差值的比较,差异显著。(4)胰岛素强化治疗后MCP-1水平更明显接近正常对照组,两者比较,P>0.05,差异无统计学意义。胰岛素常规治疗后未能达到正常对照组水平,两者比较P<0.01差异显著。(5)2型糖尿病患者MCP-1的水平与HOMA-IR呈明显的正相关。结论:(1)2型糖尿病患者经胰岛素治疗后血清单核细胞趋化蛋白-1(MCP-1)的水平明显下降。胰岛素可能通过降低MCP-1的水平而发挥抗炎作用。强化治疗组降低MCP-1的水平更明显,治疗效果更显著。(2)本研究证实2型糖尿病患者MCP-1的水平与HOMA-IR呈明显的正相关。
Forty-eight patients with type 2 diabetes diagnosed without insulin were randomly divided into 2 groups, of which 24 were intensive treatment group and 24 were conventional treatment group. Another 24 healthy people choose to take the control. To observe the changes of serum monocyte chemoattractant protein-1 (MCP-1) before and after intensive insulin treatment. Results: (1) There was no significant difference in MCP-1 levels between the intensive insulin treatment group and the conventional treatment group before treatment. Two groups before treatment compared with the normal control group, the difference was significant. (2) The levels of MCP-1 in the two groups before and after treatment were significantly different (P <0.05, P <0.01). (3) The difference between before and after treatment in insulin-intensive treatment group and conventional treatment group was significant difference. (4) After intensive insulin treatment MCP-1 levels more significantly close to the normal control group, the two were compared, P> 0.05, the difference was not statistically significant. Insulin routine treatment fails to reach the level of the normal control group, the difference between the two P <0.01 significant. (5) There was a significant positive correlation between MCP-1 level and HOMA-IR in type 2 diabetic patients. Conclusions: (1) The level of serum monocyte chemoattractant protein-1 (MCP-1) in patients with type 2 diabetes mellitus is significantly decreased after insulin treatment. Insulin may exert an anti-inflammatory effect by decreasing the level of MCP-1. Intensive treatment group to reduce the level of MCP-1 is more obvious, the treatment effect is more pronounced. (2) This study confirmed that the level of MCP-1 in type 2 diabetic patients was positively correlated with HOMA-IR.